Abstract: It is intended to provide a novel method for treating a cancer using an FGFR inhibitor that exhibits a remarkably excellent antitumor effect and has fewer side effects. The present invention provides a combination preparation for the treatment of a malignant tumor comprising a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof, and one or more additional compound(s) having an antitumor effect or pharmaceutically acceptable salt(s) thereof, and a pharmaceutical composition comprising both the active ingredients. The present invention also provides an antitumor effect enhancer, an antitumor agent, a kit for malignant tumor treatment, etc. comprising a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: A porous composite includes a porous base material and a porous collection layer provided on a collection surface of the base material. The collection layer includes particles deposited in pores of the collection surface. In a plan view of the collection surface, the proportion of the area of a covered region that is covered with the collection layer out of the collection surface is less than or equal to 70%, and the proportion of the area of a pore region out of a non-covered region that is not covered with the collection layer is less than or equal to 15%.

Abstract: A vehicle control apparatus includes front-wheel and rear-wheel driving systems, and a control system. The front-wheel driving system includes a first travel motor mechanically coupled to a front wheel of a vehicle and a first accumulator electrically coupled to the first travel motor. The rear-wheel driving system includes a second travel motor mechanically coupled to a rear wheel of the vehicle and a second accumulator electrically coupled to the second travel motor. The control system includes one or more processors and one or more memories communicably coupled to the one or more processors, and controls the first and second travel motors. When a difference between an SOC of the first accumulator and an SOC of the second accumulator is greater than a threshold value, the one or more processors change a torque distribution ratio between the first and second travel motors from a reference distribution ratio.

Abstract: It is intended to provide a novel method for treating a cancer using an FGFR inhibitor that exhibits a remarkably excellent antitumor effect and has fewer side effects. The present invention provides a combination preparation for the treatment of a malignant tumor comprising a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof, and one or more additional compound(s) having an antitumor effect or pharmaceutically acceptable salt(s) thereof, and a pharmaceutical composition comprising both the active ingredients. The present invention also provides an antitumor effect enhancer, an antitumor agent, a kit for malignant tumor treatment, etc. comprising a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: When the porous ceramic structure contains Co together with Fe or Mn, the Co content is higher than or equal to 0.1 mass % and lower than or equal to 3.0 mass % in terms of Co3O4, and when the porous ceramic structure contains Co without containing Fe and Mn, the Co content is higher than or equal to 0.2 mass % and lower than or equal to 6.0 mass % in terms of Co3O4. The Ce content is higher than or equal to 0.1 mass % and lower than or equal to 10 mass % in terms of CeO2. The Fe/Mn/Co ratio is higher than or equal to 0.8 and lower than or equal to 9.5. The content of the metal oxide particles is higher than or equal to 0.3 mass % and lower than or equal to 8.0 mass %.

Abstract: When the porous ceramic structure contains Co together with Fe or Mn, the Co content is higher than or equal to 0.1 mass % and lower than or equal to 3.0 mass % in terms of Co3O4, and when the porous ceramic structure contains Co without containing Fe and Mn, the Co content is higher than or equal to 0.2 mass % and lower than or equal to 6.0 mass % in terms of Co3O4. The Ce content is higher than or equal to 0.1 mass % and lower than or equal to 10 mass % in terms of CeO2. The Fe/Mn/Co ratio is higher than or equal to 0.8 and lower than or equal to 9.5. The porous ceramic structure contains more than or equal to 0.03 percent and less than or equal to 2.5 percent by mass of Zn in terms of ZnO.

Abstract: A porous ceramic structure includes a porous honeycomb structure composed primarily of cordierite, and Ce- and Zr-containing particles fixedly attached to the honeycomb structure. The Ce- and Zr-containing particles contain Ce and Zr. The Ce- and Zr-containing particles have a fixedly attached portion located inside the honeycomb structure and a protrusion contiguous with the fixedly attached portion and protruding from the honeycomb structure.

Abstract: It is intended to provide a novel method for treating a cancer using an FGFR inhibitor that exhibits a remarkably excellent antitumor effect and has fewer side effects. The present invention provides a combination preparation for the treatment of a malignant tumor comprising a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof, and one or more additional compound(s) having an antitumor effect or pharmaceutically acceptable salt(s) thereof, and a pharmaceutical composition comprising both the active ingredients. The present invention also provides an antitumor effect enhancer, an antitumor agent, a kit for malignant tumor treatment, etc. comprising a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: Provided is a novel combination therapy that exhibits excellent antitumor effects, and that uses an FGFR-inhibiting compound and an MEK inhibitor. An antitumor agent contains (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidin-1-yl)prop-2-en-1-one or a salt thereof as an active ingredient and is administered in combination with an MEK inhibitor.

Abstract: A pharmaceutical composition for treating cartilage dysplasia, comprising 1-[(3S)-3-[4-amino-3-[2-(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-pyrrolidinyl]-2-propen-1-one or a pharmaceutically acceptable salt thereof, and a treatment method using the pharmaceutical composition.

Abstract: When the porous ceramic structure contains Co together with Fe or Mn, the Co content is higher than or equal to 0.1 mass % and lower than or equal to 3.0 mass % in terms of Co3O4, and when the porous ceramic structure contains Co without containing Fe and Mn, the Co content is higher than or equal to 0.2 mass % and lower than or equal to 6.0 mass % in terms of Co3O4. The ratio of the sum of the Fe content in terms of Fe2O3, the Mn content in terms of Mn2O3, and the Co content in terms of Co3O4 to the Ce content in terms of CeO2 is higher than or equal to 0.8 and lower than or equal to 9.5.

Abstract: The present invention provides a pharmaceutical composition for treating a patient with an FGFR1 mutant-positive brain tumor, the composition comprising (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidin-1-yl)prop-2-en-1-one or a pharmaceutically acceptable salt thereof as an active ingredient; and a therapeutic method using the pharmaceutical composition.

Abstract: A porous ceramic structure includes a porous honeycomb structure composed primarily of cordierite, and Ce- and Zr-containing particles fixedly attached to the honeycomb structure. The Ce- and Zr-containing particles contain Ce and Zr. The Ce- and Zr-containing particles have a fixedly attached portion located inside the honeycomb structure and a protrusion contiguous with the fixedly attached portion and protruding from the honeycomb structure.

Abstract: Provided is a novel treatment method for cancer tumors to which endocrine therapy is to be applied, using an FGFR inhibitor (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidin-1-yl)prop-2-en-1-one or a pharmaceutically acceptable salt thereof. Further provided are a pharmaceutical composition comprising the above compound or a pharmaceutically acceptable salt thereof for use in treatment and/or prevention of tumors to which endocrine therapy is to be applied, the pharmaceutical composition being used in combination with endocrine therapy, as well as its related compound, use, method, and combination.

Abstract: When the porous ceramic structure contains Co together with Fe or Mn, the Co content is higher than or equal to 0.1 mass % and lower than or equal to 3.0 mass % in terms of Co3O4, and when the porous ceramic structure contains Co without containing Fe and Mn, the Co content is higher than or equal to 0.2 mass % and lower than or equal to 6.0 mass % in terms of Co3O4. The ratio of the sum of the Fe content in terms of Fe2O3, the Mn content in terms of Mn2O3, and the Co content in terms of Co3O4 to the Ce content in terms of CeO2 is higher than or equal to 0.8 and lower than or equal to 9.5.

Abstract: When the porous ceramic structure contains Co together with Fe or Mn, the Co content is higher than or equal to 0.1 mass % and lower than or equal to 3.0 mass % in terms of Co3O4, and when the porous ceramic structure contains Co without containing Fe and Mn, the Co content is higher than or equal to 0.2 mass % and lower than or equal to 6.0 mass % in terms of Co3O4. The Ce content is higher than or equal to 0.1 mass % and lower than or equal to 10 mass % in terms of CeO2. The Fe/Mn/Co ratio is higher than or equal to 0.8 and lower than or equal to 9.5. The porous ceramic structure contains more than or equal to 0.03 percent and less than or equal to 2.5 percent by mass of Zn in terms of ZnO.

Abstract: When the porous ceramic structure contains Co together with Fe or Mn, the Co content is higher than or equal to 0.1 mass % and lower than or equal to 3.0 mass % in terms of Co3O4, and when the porous ceramic structure contains Co without containing Fe and Mn, the Co content is higher than or equal to 0.2 mass % and lower than or equal to 6.0 mass % in terms of Co3O4. The Ce content is higher than or equal to 0.1 mass % and lower than or equal to 10 mass % in terms of CeO2. The Fe/Mn/Co ratio is higher than or equal to 0.8 and lower than or equal to 9.5. The content of the metal oxide particles is higher than or equal to 0.3 mass % and lower than or equal to 8.0 mass %.

Abstract: It is intended to provide a novel method for treating a cancer using an FGFR inhibitor that exhibits a remarkably excellent antitumor effect and has fewer side effects. The present invention provides a combination preparation for the treatment of a malignant tumor comprising a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof, and one or more additional compound(s) having an antitumor effect or pharmaceutically acceptable salt(s) thereof, and a pharmaceutical composition comprising both the active ingredients. The present invention also provides an antitumor effect enhancer, an antitumor agent, a kit for malignant tumor treatment, etc. comprising a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: A charged particle beam device is provided that performs proper beam adjustment while suppressing a decrease in MAM time, with a simple configuration without adding a lens, a sensor, or the like. The charged particle beam device includes: an optical element which adjusts a charged particle beam emitted from a charged particle source; an adjustment element which adjusts an incidence condition of the charged particle beam with respect to the optical element; and a control device which controls the adjustment element, wherein the control device determines a difference between a first feature amount indicating a state of the optical element based on the condition setting of the optical element, and a second feature amount indicating a state where the optical element reaches based on the condition setting and executes adjustment by the adjustment element when the difference is greater than or equal to a predetermined value.

Abstract: It is intended to provide a novel method for treating a cancer using an FGFR inhibitor that exhibits a remarkably excellent antitumor effect and has fewer side effects. The present invention provides a combination preparation for the treatment of a malignant tumor comprising a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof, and one or more additional compound(s) having an antitumor effect or pharmaceutically acceptable salt(s) thereof, and a pharmaceutical composition comprising both the active ingredients. The present invention also provides an antitumor effect enhancer, an antitumor agent, a kit for malignant tumor treatment, etc. comprising a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof.